Frontlight ResearchEarly access
Not yet recruitingPhase 1/2
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy
Key facts
- Who runs it
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.
- Where
- China8 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 55 people, planned
- Started
- Aug 2026
- Expected to end
- Mar 2030
- Type of study
- Interventional
- Treatments tested
- FKC289 injection
- Record updated
- 14 August 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Voluntarily signed the informed consent form (ICF)
- Aged between 18-70 years old (inclusive)
- Histologically confirmed diagnosis of primary membranous nephropathy by renal biopsy obtained within the past 2 years
- Relapsed or refractory disease
- Anti-PLA2R antibody > 50 RU/mL
- 24-hour urine protein > 3.5 g at screening
- No active systemic infection (e.g., infectious pneumonia, pulmonary tuberculosis) within 2 weeks prior to leukapheresis
- Adequate bone marrow and major organ function (including hepatic, renal, cardiac, and pulmonary)
Who cannot take part
- Secondary membranous nephropathy or patients with a prior diagnosis of other renal diseases
- Presence of any clinically significant cardiovascular disease within 6 months prior to screening
- Clinically significant central nervous system (CNS) disease or pathological abnormality
- History of solid organ transplantation (e.g., heart, lung, kidney, liver)
- Presence of complete intestinal obstruction
- Moderate to severe pleural effusion or ascites that is difficult to control with conventional treatment and requires continuous catheter drainage
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory Primary Membranous Nephropathy.The primary objectives are to assess the safety of FKC289 and to establish the recommended Phase II dose (RP2D).And this Phase II study is designed to evaluate the efficacy of FKC289.The primary objectives are to assess proportion of subjects achieving clinical response (including complete or partial response) at 6 months.
The group in the trial
- FKC289 injectionTreatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07765537, who can take part
- Record updated
- 14 August 2026